Professor, Medical Research Institute 
Email: Jinfang_zhang@whu.edu.cn
Jinfang Zhang, PhD
Research Areas:
Molecular mechanisms of targeted therapies and immunotherapies for cancer
Selected Publications: (12 out of 32)
1. Zhang J*, Bu X*, Wang H*, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ#, Sicinski P#, Wei W# (2018). Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance. Nature, 553(7686): 91-95.
2. Zhang J*, Dang F*, Ren J, Wei W (2018). PD-L1 regulation and its role in cancer immunotherapy. Trends in Biochemical Sciences, 43(12): 1014-1032.
3. Zhang J*, Chen M*, Zhu Y*, Dai X, Ren J, Ren S, Shulga YV, Beca F, Gan W, Wu F, Lin YM, DeCaprio JA, Beck AH, Lu KP, Huang J, Zhao C, Sun Y, Gao X#, Pandolfi PP#, Wei W# (2018). SPOP promotes Nanog destruction to suppress stem cell traits and prostate cancer progression. Developmental Cell, published online Dec. 27, 2018.
4. Wan L*, Xu K*, Wei Y*, Zhang J*, Han T, Fry C, Zhang Z, Wan Y, Huang L, Yuan M, Xia W, Chang W, Huang W, Liu C, Chang Y, Liu J, Wu Y, Jin V, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung MC, Wei W (2018). Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. Molecular Cell, 69(2): 279-291.
5. Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades N, Wei W, Ding Q#, Zhang J# (2017). Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Letters, 385: 207-214.
6. Wang B*, Jie Z*, Joo D, Ordureau A, Liu P, Gan W, Guo J, Zhang J, North BJ, Dai X, Cheng X, Bian X, Zhang L, Harper JW, Sun S# and Wei W# (2017). TRAF2 and OTUD7B govern a ubiquitin-dependent switch regulating mTORC2 signaling complex. Nature, 545(7654): 365-369.
7. Zhang J*, Xu K*, Liu P, Geng Y, Wang B, Gan W, Guo J, Wu F, Chin YR, Berrios C, Lien EC, Toker A, DeCaprio JA, Sicinski P, Wei W (2016). Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt. Molecular Cell, 62(6): 929-942.
8. Guo J, Chakraborty AK, Liu P, Gan W, Zheng X, Inuzuka H, Wang B, Zhang J, Zhang, L, Novak, J, Yuan, M, Cheng, JQ, Toker, A, Signroretti, S, Zhang, Q, Asara, JM, Kaelin, Jr, WG, Wei, W (2016). pVHL suppresses kinase activity of Akt in a proline-hydroxylation dependent manner. Science, 353(6302): 929-932.
9. Wang L*, Zhang J*, Wan L*, Zhou X, Wang Z, Wei W (2015). Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacology & Therapeutics, 151: 141-151.
10. Zhang J*, Wan L*, Dai X, Sun Y, Wei W (2014). Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Biochim Biophys Acta (BBA)-Reviews on Cancer, 1845(2): 277-293.
11. Zhang J, Bai D, Ma X, Guan J, Zheng X (2014). hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14. Oncogene, 33(2): 246-254.
12. Zhang J, Zhang F, Zheng X (2010). Depletion of hCINAP by RNA interference causes defects in Cajal body formation, histone transcription, and cell viability. Cell Mol Life Sci, 67:1907-1918.
